Moderna, Inc. (NASDAQ:MRNA - Get Free Report) President Stephen Hoge sold 291 shares of the company's stock in a transaction dated Friday, November 29th. The shares were sold at an average price of $42.79, for a total transaction of $12,451.89. Following the completion of the transaction, the president now directly owns 1,443,567 shares of the company's stock, valued at approximately $61,770,231.93. The trade was a 0.02 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.
Stephen Hoge also recently made the following trade(s):
- On Tuesday, September 3rd, Stephen Hoge sold 318 shares of Moderna stock. The stock was sold at an average price of $76.99, for a total value of $24,482.82.
Moderna Trading Up 2.8 %
NASDAQ:MRNA opened at $44.26 on Tuesday. The firm has a market capitalization of $17.03 billion, a P/E ratio of -7.60 and a beta of 1.69. The business has a 50 day simple moving average of $51.98 and a 200 day simple moving average of $90.21. The company has a debt-to-equity ratio of 0.05, a current ratio of 4.39 and a quick ratio of 4.20. Moderna, Inc. has a 12-month low of $35.80 and a 12-month high of $170.47.
The Biggest Financial Event of 2024?
From InvestorPlace | Ad
Should you buy, sell, or hold your stock?
To find the answer, let’s look at the actions of the world’s wealthiest investors…
Right now, the world’s wealthiest investors are preparing for what could become ‘the biggest financial event’ of 2024.
Click here for the step-by-step details
Moderna (NASDAQ:MRNA - Get Free Report) last announced its quarterly earnings results on Thursday, November 7th. The company reported $0.03 earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.89) by $1.92. Moderna had a negative net margin of 43.77% and a negative return on equity of 17.68%. The company had revenue of $1.90 billion during the quarter, compared to the consensus estimate of $1.25 billion. During the same quarter in the previous year, the company posted ($1.39) earnings per share. The company's revenue for the quarter was up 3.8% compared to the same quarter last year. Equities research analysts predict that Moderna, Inc. will post -9.44 EPS for the current year.
Analyst Upgrades and Downgrades
A number of brokerages have issued reports on MRNA. Royal Bank of Canada reaffirmed a "sector perform" rating and issued a $75.00 target price on shares of Moderna in a research report on Thursday, September 19th. Jefferies Financial Group dropped their price target on shares of Moderna from $65.00 to $55.00 and set a "hold" rating for the company in a research note on Tuesday, October 15th. The Goldman Sachs Group reduced their price objective on shares of Moderna from $178.00 to $139.00 and set a "buy" rating on the stock in a research note on Monday, September 16th. Berenberg Bank started coverage on shares of Moderna in a research report on Tuesday, November 19th. They issued a "hold" rating and a $42.00 target price for the company. Finally, Hsbc Global Res raised shares of Moderna from a "hold" rating to a "strong-buy" rating in a research report on Monday, November 18th. Three analysts have rated the stock with a sell rating, twelve have given a hold rating, five have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of "Hold" and a consensus target price of $83.33.
Get Our Latest Research Report on Moderna
Institutional Inflows and Outflows
Several institutional investors and hedge funds have recently bought and sold shares of the company. Inspire Trust Co. N.A. boosted its position in shares of Moderna by 73.5% during the third quarter. Inspire Trust Co. N.A. now owns 16,525 shares of the company's stock worth $1,104,000 after buying an additional 7,000 shares during the period. Teachers Retirement System of The State of Kentucky boosted its position in Moderna by 1.4% during the 3rd quarter. Teachers Retirement System of The State of Kentucky now owns 287,887 shares of the company's stock worth $19,239,000 after acquiring an additional 3,978 shares during the period. Toronto Dominion Bank grew its stake in shares of Moderna by 23.7% in the third quarter. Toronto Dominion Bank now owns 131,477 shares of the company's stock worth $8,787,000 after purchasing an additional 25,177 shares in the last quarter. Geode Capital Management LLC increased its holdings in shares of Moderna by 2.6% during the third quarter. Geode Capital Management LLC now owns 7,069,580 shares of the company's stock valued at $470,670,000 after purchasing an additional 178,115 shares during the period. Finally, Groupama Asset Managment raised its stake in shares of Moderna by 29.1% during the third quarter. Groupama Asset Managment now owns 21,838 shares of the company's stock valued at $1,459,000 after purchasing an additional 4,920 shares in the last quarter. Institutional investors own 75.33% of the company's stock.
About Moderna
(
Get Free Report)
Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
